Abbott Laboratories 8-K Summary
Business Context and Reporting Period
Abbott Laboratories (ABT) filed this Form 8-K on October 19, 2022, to report its results of operations for the third quarter of 2022. The filing incorporates by reference a press release (Exhibit 99.1) containing the detailed financial results.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the existence of these metrics in the attached press release but does not list them within the 8-K body text itself.
Material Changes and Non-GAAP Adjustments
Abbott utilizes non-GAAP financial measures to assess performance, adjusting for unusual or unpredictable items. The filing lists the following specific adjustments excluded from non-GAAP results:
- Expenses associated with acquisitions, restructuring actions, and cost reduction initiatives.
- Costs related to a voluntary recall and certain regulatory costs.
- Certain litigation expenses and impairment of certain assets.
- Tax benefits associated with specified items and net tax expense from the resolution of prior-year tax positions.
- Excess tax benefits associated with share-based compensation.
- Intangible amortization expense.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, outlook figures, or detailed risk factors within the text provided. Management cautions investors to consider non-GAAP measures in addition to, and not as a substitute for, GAAP financial measures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2022 revenue, net earnings, and cash flow figures.
- Verify the magnitude of the "voluntary recall" and "certain litigation" costs mentioned as non-GAAP adjustments.
- Confirm the impact of intangible amortization on reported margins.
- Check for any updated full-year 2022 guidance in the referenced press release.